<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03874871</url>
  </required_header>
  <id_info>
    <org_study_id>2018KT86</org_study_id>
    <nct_id>NCT03874871</nct_id>
  </id_info>
  <brief_title>Function Preserving Gastrectomy for T1/2 Gastric Cancer Patients</brief_title>
  <official_title>Function Preserving Gastrectomy for T1/2 Gastric Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Municipal Science &amp; Technology Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The real world based multi-cohorts study aims to evaluate the safety and effectiveness of
      function preserving gastrectomy including pylorus-preserving distal gastrectomy, proximal
      gastrectomy and wedge gastrectomy for T1 and T2 gastric cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric cancer patients with clinical stage T1/2 will be screened for the study. For the
      patients enrolled, a multidisciplinary discussion will be performed to evaluate the proper
      gastrectomy for the patients and functional preserving gastrectomy will be considered for the
      indicated patients. For patients not proper for functional preserving gastrectomy, standard
      gastrectomies will be suggested. After surgery, a close follow up will be performed. During
      the study, a thorough data collection will be performed to evaluate the safety and
      effectiveness of functional preserving gastrectomy and recovery and postoperative function of
      remnant stomach.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 20, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Pathologic R0 resection rate with negative proximal and distal margin based on the postoperative pathologic result.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extent of lymphadenectomy of different gastrectomy</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>resected lymph node number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of metastatic lymph node</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>metastatic lymph node number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative morbidity</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>postoperative complication rate according to the clavien-dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative mortality</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>postoperative death rate with 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>remnant stomach function</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>volume of remnant stomach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>disease free survival after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life after surgery</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>Quality of life evaluated by EORTC-STO22 by questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>overall survival after surgery</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Gastrostomy</condition>
  <arm_group>
    <arm_group_label>Function preserving gastrectomy</arm_group_label>
    <description>After baseline evaluation, a multidisciplinary discussion will be performed for the patients to choose the proper gastrectomy. For patients indicated for function preserving gastrectomy (including pylorus preserving gastrectomy, proximal gastrectomy, partial gastrectomy), they will receive the function preserving gastrectomy. After the surgery, a close follow up is performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard gastrectomy</arm_group_label>
    <description>After baseline evaluation, a multidisciplinary discussion will be performed for the patients to choose the proper gastrectomy. For patients not indicated for function preserving gastrectomy, they will receive standard gastrectomy. After the surgery, a close follow up is performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Function preserving gastrectomy</intervention_name>
    <description>Function preserving gastrectomy include pylorus preserving gastrectomy, proximal gastrectomy, and partial gastrectomy.</description>
    <arm_group_label>Function preserving gastrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard gastrectomy</intervention_name>
    <description>Standard gastrectomy include distal gastrectomy and total gastrectomy with standard lymphadenectomy according to the Japanese gastric cancer treatment guideline.</description>
    <arm_group_label>Standard gastrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Non-advanced gastric cancer patients with the clinical stage cT1-2 that are indicated for
        gastrectomy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Karnofsky performance over 70%

          -  Histologically proven gastric or gastroesophageal joint adenocarcinoma with clinical
             stage T1-2N0-3M0

          -  No severe comorbidity with estimated survival less than 5 years

        Exclusion Criteria:

          -  pregnancy

          -  Signs of distant metastases

          -  received chemotherapy, radiotherapy, immune therapy

          -  received gastrectomy

          -  other malignant tumors within 5 years except for cured skin cancer and cervical caner
             in situ.

          -  uncontrolled epilepsy, central nervus system disease or mental disease that affect the
             compliance of treatment and follow-up

          -  severe heart disease

          -  organ transplantation that needs immunosuppressor

          -  emergency surgery due to hemorrhage, perforation and ileus of gastric cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ziyu Li, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rulin Miao, MD</last_name>
    <phone>86-10-88196598</phone>
    <email>miaorulin@outlook.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 4, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Ziyu Li, MD</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>function preserving gastrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

